Unit of General Pathology, Center for Advanced Studies and Technology (CAST), University G. d'Annunzio Chieti-Pescara, Chieti, Italy.
Department of Medicine and Aging Sciences, University G. d'Annunzio Chieti-Pescara, Chieti, Italy.
J Hematol Oncol. 2019 Nov 19;12(1):114. doi: 10.1186/s13045-019-0802-x.
Clonal evolution of chronic lymphocytic leukemia (CLL) often follows chemotherapy and is associated with adverse outcome, but also occurs in untreated patients, in which case its predictive role is debated. We investigated whether the selection and expansion of CLL clone(s) precede an aggressive disease shift. We found that clonal evolution occurs in all CLL patients, irrespective of the clinical outcome, but is faster during disease progression. In particular, changes in the frequency of nucleotide variants (NVs) in specific CLL-related genes may represent an indicator of poor clinical outcome.
慢性淋巴细胞白血病(CLL)的克隆进化通常发生在化疗之后,并与不良预后相关,但也发生在未经治疗的患者中,此时其预测作用存在争议。我们研究了 CLL 克隆(s)的选择和扩增是否先于侵袭性疾病进展。我们发现,克隆进化发生在所有 CLL 患者中,与临床结果无关,但在疾病进展过程中更快。特别是,特定与 CLL 相关基因中的核苷酸变异(NV)频率的变化可能是临床结果不良的一个指标。